Astellas Pharma €800 million acquisition of Ogeda

Overview:

• Astellas Pharma has completed the €800 million acquisition of Ogeda.
• The target is a privately owned Belgian drug discovery company.
• The buyer is Japanese pharmaceutical company that is part of the Mitsubishi UFJ Financial Group.
• This deal is the latest in a string of recent international purchases by the company, including the $379 million acquisition of Massachusetts-based Ocata Therapeutics in February 2016 and the €422 million acquisition of Ganymed Pharmaceuticals, which is based in Mainz, Germany.

Jon Moore - Journalist